Products / Projects
OWN DRUG PRODUCTS AND PROJECT PIPELINES
- IPSS’s rich pipeline of drug product candidates demonstrates the innovative drug development program of the NCE’s: Cis-4-Hydroxy-L-proline (CHP) and Cis-Oxoplatin and the application of the Siosomes ® Technology for the delivery and targeting of anti-cancer drugs, peptides, proteins, and genetic materials such as siRNA and other pharmaceuticals.
- Backed by decades of experience and expertise, we and our partners are able to streamline clinical development time and substantially increase the probability of the late-stage product success. The proof is in our innovative pipeline and technologies and their potential to have a unique and positive impact for patients:
SIOSOMES TECHNOLOGY - DRUG PRODUCT PIPELINE
Our long years of research and development showed that silanes and sugarorgano silicon compounds such as cationic, anionic and PEGylated compounds, comprised of di(acyloxy)dialkoxysilanes, di(acyloxy)diarylsilanes, tetra(acyloxy)silanes or aminosugar organosilicon compounds and their derivatives – open up a wide range of possibilities for drug delivery and targeting.
By appropriate composition of the four substitutes at the central silicon atom, the properties and uses of both the non-aggregated organosilicon compounds (Silanes, sugar Silanes and derivatives) and the vesicles formed by these compounds (Siosomes®) can be varied on a broad basis, thus enabling adaptation to specific and customized delivery and targeting of a particular molecule such as a pharmaceutical, biological or cosmetic agent.
A large number of developed and patented organosilicon compounds have been synthesized and investigated for their encapsulation of active agents properties. Silanes could be prepared as:
- Cationic organosilicon compounds and siosomes
- Anionic organosilicon compounds and siosomes
- Zwitter-ionic organosilicon compounds and siosomes
- PEGylated organosilicon compounds and siosomes
- Protein-conjugated organosilicon compounds and siosomes
A number of these organosilicon compounds and Siosomes® are toxicologically and pharmacologically INERT, meaning that they are suitable for the encapsulation of active agents, cosmetics and proteins.
Siosomes® Product Pipeline
OWN DRUG PROJECTS UNDER DEVELOPMENT
- Oral Delivery of Peptides and Proteins using the Siosomes®Technology
- Anti-Alzheimer’s Disease-Proof of Concept (POC) –ELPIS 207
- CNS Delivery of Siosomal Drugs to the Brain
- SIO-dermal development of 5-FU